Myomo Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.… Read more
Myomo Inc (MYO) - Net Assets
Latest net assets as of September 2025: $14.63 Million USD
Based on the latest financial reports, Myomo Inc (MYO) has net assets worth $14.63 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.08 Million) and total liabilities ($19.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.63 Million |
| % of Total Assets | 42.92% |
| Annual Growth Rate | 42.57% |
| 5-Year Change | 113.69% |
| 10-Year Change | N/A |
| Growth Volatility | 223.51 |
Myomo Inc - Net Assets Trend (2014–2024)
This chart illustrates how Myomo Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Myomo Inc (2014–2024)
The table below shows the annual net assets of Myomo Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $24.71 Million | +174.93% |
| 2023-12-31 | $8.99 Million | +41.36% |
| 2022-12-31 | $6.36 Million | -58.73% |
| 2021-12-31 | $15.41 Million | +33.24% |
| 2020-12-31 | $11.57 Million | +533.82% |
| 2019-12-31 | $1.82 Million | -71.60% |
| 2018-12-31 | $6.43 Million | -48.37% |
| 2017-12-31 | $12.45 Million | +171.00% |
| 2016-12-31 | $-17.53 Million | -1210.04% |
| 2015-12-31 | $-1.34 Million | -287.91% |
| 2014-12-31 | $712.11K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Myomo Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8758581400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.44K | 0.01% |
| Other Comprehensive Income | $-14.41K | -0.06% |
| Other Components | $127.84 Million | 517.27% |
| Total Equity | $24.71 Million | 100.00% |
Myomo Inc Competitors by Market Cap
The table below lists competitors of Myomo Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MWB0
XETRA:MWB0
|
$19.95 Million |
|
DeepMarkit Corp.
NASDAQ:MKTSF
|
$19.95 Million |
|
Rushil Decor Limited
NSE:RUSHIL
|
$19.96 Million |
|
MARINUS PHARMAC. DL-001
F:61Y
|
$19.96 Million |
|
Kothari Petrochemicals Limited
NSE:KOTHARIPET
|
$19.93 Million |
|
FREELANCE.COM EO -08
F:9B4
|
$19.93 Million |
|
HUDSON GLOBAL INC.DL-001
F:HDH1
|
$19.93 Million |
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
$19.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Myomo Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,989,350 to 24,714,057, a change of 15,724,707 (174.9%).
- Net loss of 6,183,729 reduced equity.
- Share repurchases of 21,131,930 reduced equity.
- New share issuances of 20,368,791 increased equity.
- Other comprehensive income decreased equity by 98,075.
- Other factors increased equity by 22,769,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.18 Million | -25.02% |
| Share Repurchases | $21.13 Million | -85.51% |
| Share Issuances | $20.37 Million | +82.42% |
| Other Comprehensive Income | $-98.08K | -0.4% |
| Other Changes | $22.77 Million | +92.13% |
| Total Change | $- | 174.93% |
Book Value vs Market Value Analysis
This analysis compares Myomo Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.03x to 1.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $21.40 | $0.72 | x |
| 2015-12-31 | $-40.17 | $0.72 | x |
| 2016-12-31 | $-2.73 | $0.72 | x |
| 2017-12-31 | $86.47 | $0.72 | x |
| 2018-12-31 | $15.67 | $0.72 | x |
| 2019-12-31 | $3.29 | $0.72 | x |
| 2020-12-31 | $3.47 | $0.72 | x |
| 2021-12-31 | $2.64 | $0.72 | x |
| 2022-12-31 | $0.90 | $0.72 | x |
| 2023-12-31 | $0.30 | $0.72 | x |
| 2024-12-31 | $0.65 | $0.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Myomo Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.00%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.71x
- Recent ROE (-25.02%) is above the historical average (-162.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -495.40% | -386.29% | 0.30x | 4.28x | $-3.60 Million |
| 2015 | 0.00% | -649.90% | 0.46x | 0.00x | $-4.35 Million |
| 2016 | 0.00% | -327.84% | 0.67x | 0.00x | $-1.86 Million |
| 2017 | -97.20% | -776.04% | 0.11x | 1.12x | $-13.34 Million |
| 2018 | -160.55% | -422.11% | 0.30x | 1.29x | $-10.96 Million |
| 2019 | -587.11% | -279.15% | 0.58x | 3.62x | $-10.90 Million |
| 2020 | -99.99% | -152.49% | 0.52x | 1.27x | $-12.72 Million |
| 2021 | -67.31% | -74.86% | 0.69x | 1.30x | $-11.91 Million |
| 2022 | -168.59% | -68.92% | 1.53x | 1.60x | $-11.36 Million |
| 2023 | -90.64% | -42.34% | 1.32x | 1.62x | $-9.05 Million |
| 2024 | -25.02% | -19.00% | 0.77x | 1.71x | $-8.66 Million |
Industry Comparison
This section compares Myomo Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Myomo Inc (MYO) | $14.63 Million | -495.40% | 1.33x | $19.94 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |